(Transnasal Humidified Rapid-Insufflation Ventilatory Exchange)

 

Optiflow THRIVE™ provides effective oxygenation and extends safe apnoea time during anaesthesia. 1,2,3,4

If you have any enquiries about our F&P Optiflow Thrive product, please provide the following information so we can connect you with a Fisher & Paykel Healthcare representative and contact you. 

 
Privacy Statement:*:
 
  * Required Information  
 

Sign up to receive email updates on new clinical publications and registered clinical trials on Optiflow THRIVE


Optiflow Nasal High Flow mechanisms of action

Improving patient care and outcomes through respiratory support, airway hydration, patient comfort and supplemental oxygen (if required).

For safety and performance information, please refer to the user instructions provided with our products. Optiflow and Optiflow THRIVE are trademarks of Fisher and Paykel Healthcare Limited.
For patent information, see www.fphcare.com/ip
 
1. Patel, A., & Nouraei, S. R. (2015). Transnasal Humidified Rapid‐Insufflation Ventilatory Exchange (THRIVE): a physiological method of increasing apnoea time in patients with difficult airways. Anaesthesia, 70(3), 323-329. 2. Gustafsson, I. M., Lodenius, Å., Tunelli, J., Ullman, J., & Jonsson Fagerlund, M. (2017). Apnoeic oxygenation in adults under general anaesthesia using Transnasal Humidified Rapid-Insufflation Ventilatory Exchange (THRIVE)–a physiological study. BJA: British Journal of Anaesthesia, 118(4), 610-617. 3.Rajan, S., et al. (2018). "Effectiveness of transnasal humidified rapid-insufflation ventilatory exchange versus traditional preoxygenation followed by apnoeic oxygenation in delaying desaturation during apnoea: A preliminary study." Indian J Anaesth 62(3): 202-207. 4. Wong, D. T., et al. (2019). “High-Flow Nasal Oxygen Improves Safe Apnea Time in Morbidly Obese Patients Undergoing General Anesthesia: A Randomized Controlled Trial”. Anesth Analg [Ahead of print)]